Intellia Therapeutics Statistics
Share Statistics
Intellia Therapeutics has 103.58M
shares outstanding. The number of shares has increased by 7.3%
in one year.
| Shares Outstanding | 103.58M |
| Shares Change (YoY) | 7.3% |
| Shares Change (QoQ) | 1.64% |
| Owned by Institutions (%) | 98.29% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 11,932 |
| FTD / Avg. Volume | 0.33% |
Short Selling Information
The latest short interest is 28.75M, so 27.75% of the outstanding
shares have been sold short.
| Short Interest | 28.75M |
| Short % of Shares Out | 27.75% |
| Short % of Float | 31.59% |
| Short Ratio (days to cover) | 9.6 |
Valuation Ratios
The PE ratio is -2.22 and the forward
PE ratio is -1.94.
Intellia Therapeutics's PEG ratio is
0.71.
| PE Ratio | -2.22 |
| Forward PE | -1.94 |
| PS Ratio | 19.91 |
| Forward PS | 0.3 |
| PB Ratio | 1.32 |
| P/FCF Ratio | -3.25 |
| PEG Ratio | 0.71 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Intellia Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.77,
with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.77 |
| Quick Ratio | 5.77 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | -0.41 |
| Debt / FCF | -0.59 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $143,615.38 |
| Profits Per Employee | $-1,287,893.3 |
| Employee Count | 403 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -67.59% in the
last 52 weeks. The beta is 2.33, so Intellia Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.33 |
| 52-Week Price Change | -67.59% |
| 50-Day Moving Average | 8.24 |
| 200-Day Moving Average | 14.33 |
| Relative Strength Index (RSI) | 51.88 |
| Average Volume (20 Days) | 3,582,548 |
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of 57.88M
and earned -519.02M
in profits. Earnings per share was -5.25.
| Revenue | 57.88M |
| Gross Profit | 47.59M |
| Operating Income | -534.26M |
| Net Income | -519.02M |
| EBITDA | -508.74M |
| EBIT | -534.26M |
| Earnings Per Share (EPS) | -5.25 |
Full Income StatementBalance Sheet
The company has 189.18M in cash and 210.2M in
debt, giving a net cash position of -21.02M.
| Cash & Cash Equivalents | 189.18M |
| Total Debt | 210.2M |
| Net Cash | -21.02M |
| Retained Earnings | -2.18B |
| Total Assets | 1.19B |
| Working Capital | 529.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -348.88M
and capital expenditures -5.78M, giving a free cash flow of -354.66M.
| Operating Cash Flow | -348.88M |
| Capital Expenditures | -5.78M |
| Free Cash Flow | -354.66M |
| FCF Per Share | -3.59 |
Full Cash Flow StatementMargins
Gross margin is 82.23%, with operating and profit margins of -923.1% and -896.77%.
| Gross Margin | 82.23% |
| Operating Margin | -923.1% |
| Pretax Margin | -896.77% |
| Profit Margin | -896.77% |
| EBITDA Margin | -879% |
| EBIT Margin | -923.1% |
| FCF Margin | -612.78% |
